Home > Insider Trading > Filing (0001209191-21-046027)

Filing Details

Accession Number:: 0001209191-21-046027
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-07-08 18:14:53
Reporting Period:: 2021-07-06

Accepted Time:: 2021-07-08 18:14:53
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1576885	Acumen Pharmaceuticals Inc.	ABOS	Biological Products, (No Disgnostic Substances) (2836)	364108129

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1804350	D. Robert Hardie	210 Ridge Mcintire Road, Suite 350 Charlottesville VA 22903		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-07-06	1,124,830	$0.00	1,124,830	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-07-06	2,076,326	$0.00	3,201,156	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2021-07-06	750,000	$16.00	3,951,156	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Preferred Stock	Disposition	2021-07-06	1,124,830	$0.00	1,124,830	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-07-06	2,076,326	$0.00	2,076,326	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Consists of 562,415 shares of common stock issuable upon conversion of Series A-1 preferred stock held by H7 Holdings LLC, and 562,415shares of common stock issuable upon conversion of Series A-1 preferred stock held by Level One Partners, LLC. Robert D. Hardie is theManager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by each entity. TheReporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to the extent ofhis pecuniary interest therein.
Consists of 1,038,163 shares of common stock issuable upon conversion of Series B convertible preferred stock held by H7 Holdings LLC, and1,038,163 shares of common stock issuable upon conversion of Series B convertible preferred stock held by Level One Partners, LLC. Robert D.Hardie is the Manager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by eachentity. The Reporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to theextent of his pecuniary interest therein.
Consists of 375,000 shares of common stock held by H7 Holdings LLC, and 375,000 shares of common stock held by Level One Partners, LLC. Robert D. Hardie is the Manager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by each entity. The Reporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to the extent of his pecuniary interest therein.